ホーム › 非小細胞肺癌 › ミシガン州 › Ann Arbor

Ann Arbor、MIにおける非小細胞肺癌の臨床試験

Ann Arborとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

被験者募集中第3相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
他4件

18歳以上 · 全性別 · 2026/10/05更新 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

被験者募集中第2相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
Chelsea Hospital, Chelsea · 15マイル先
他3件

18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

被験者募集中第3相

University of Michigan Rogel Cancer Center, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
他2件

18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

被験者募集中第3相

Trinity Health Ann Arbor Hospital, Ann Arbor

18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

被験者募集中第2相

University of Michigan Health System, Ann Arbor
Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · 7マイル先

18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

被験者募集中第2相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
他4件

18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

被験者募集中第1相

University of Michigan Health Systems, Ann Arbor

18歳以上 · 全性別 · 2026/09/23更新 · NCT07140016

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

被験者募集中第1/2相

University of Michigan Medical School Rogel Cancer Center, Ann Arbor

18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

被験者募集中第3相

Clinical Study Site, Ann Arbor

18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

被験者募集中第2相

University of Michigan, Ann Arbor

18歳以上 · 全性別 · 2026/09/10更新 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

被験者募集中第1相

University of Michigan, Ann Arbor

18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

被験者募集中第3相

University of Michigan, Ann Arbor

18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

被験者募集中第3相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · 7マイル先

18歳以上 · 全性別 · 2026/09/03更新 · NCT06422143

Gilteritinib for the Treatment of ALK NSCLC

被験者募集中第1相

University of Michigan Comprehensive Cancer Center, Ann Arbor

18歳以上 · 全性別 · 2026/06/26更新 · NCT06225427

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

被験者募集中第1相

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor

18歳以上 · 全性別 · 2026/06/04更新 · NCT04777994

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

被験者募集中第2相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
他4件

18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

被験者募集中第2相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
他1件

18歳以上 · 全性別 · 2026/05/06更新 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

被験者募集中第2/3相

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18マイル先

18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

被験者募集中第2相

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Huron Gastroenterology PC, Ypsilanti · 7マイル先
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
他4件

18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688